Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Eupraxia Pharmaceuticals ( (TSE:EPRX) ) is now available.
Eupraxia Pharmaceuticals reported encouraging interim results from the Phase 1b/2a portion of its RESOLVE trial of EP-104GI in eosinophilic esophagitis, showing near-complete normalization of esophageal tissue health at the highest dose by week 12 and sustained improvements at lower doses out to week 36. A majority of patients who had at least 60% of their esophagus treated achieved and maintained clinical remission for up to 52 weeks after a single administration, with more than 200 patient-months of follow-up showing no serious adverse events or oral candidiasis, bolstering EP-104GI’s profile as a potentially once-yearly treatment and supporting ongoing recruitment in the randomized Phase 2b trial, with top-line data expected in 2026.
The most recent analyst rating on (TSE:EPRX) stock is a Buy with a C$16.00 price target. To see the full list of analyst forecasts on Eupraxia Pharmaceuticals stock, see the TSE:EPRX Stock Forecast page.
Spark’s Take on TSE:EPRX Stock
According to Spark, TipRanks’ AI Analyst, TSE:EPRX is a Neutral.
The score is held back primarily by weak financial performance (no revenue, sizable losses, and persistent cash burn), partially offset by a stronger balance sheet with low leverage. Technicals are supportive with a strong uptrend, but overbought momentum raises pullback risk. Valuation remains constrained due to negative earnings and no dividend support.
To see Spark’s full report on TSE:EPRX stock, click here.
More about Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company that uses its proprietary Diffusphere technology to develop locally delivered, controlled-release drugs targeting diseases with significant unmet medical need. The company is currently focused on gastrointestinal indications, including eosinophilic esophagitis (EoE), and is listed on both Nasdaq and the Toronto Stock Exchange under the symbol EPRX.
Average Trading Volume: 69,609
Technical Sentiment Signal: Buy
Current Market Cap: C$530M
See more insights into EPRX stock on TipRanks’ Stock Analysis page.